Is Thymosin Alpha-1 Legal in Virginia? How to Access It Legally

HealthRX.com

No FDA-approved route to get thymosin alpha-1 in the US

Print or save as PDF

Key numbers

  • 4 yes and 17 noFDA advisory committee vote on adding thymosin alpha-1 to the pharmacy bulks listSource: fda.gov, as cited Nov 7, 2026
  • 1.6 mgZadaxin strength per vial, a finished injection not interchangeable with bulk powderSource: fda.gov, as cited Nov 7, 2026
  • 4 weeksLength of the Italian Zadaxin course, which is not a US-approved regimenSource: fda.gov, as cited Nov 7, 2026
  • FDA status / Not approved in the US; four orphan designations, which are not approvals [1]
  • State-licensed pharmacy list / In none of the three categories (updated May 14, 2026) [2]
  • Outsourcing facility list / Category 3, nominated without adequate support (updated March 21, 2025) [3]
  • Advisory committee vote / 4 yes, 17 no, no abstentions, December 4, 2024 [4]
  • HHS peptide policy / Not among the six peptides in the October 2026 draft [5]
  • Approved in / Italy, India and Hong Kong, per FDA [1]
  • US adverse-event reports / Zero in FDA's database search of April 22, 2024 [1]

Is Thymosin Alpha-1 FDA-Approved?

No. A Drugs@FDA search found no US marketing application for thymosin alpha-1 [1]. FDA's December 2024 review notes four US orphan drug designations, but orphan designation is a separate process from approval and is not an approval [1].

It is approved as a medicine elsewhere. FDA lists Italy, where Zadaxin is authorized as an adjuvant to influenza vaccination in immunocompromised people; India, for chronic hepatitis B in adults 18 and older with compensated liver disease and virus replication; and Hong Kong [1]. The European Medicines Agency holds only an orphan designation, for hepatocellular carcinoma [1]. Zadaxin is a finished injection sold as 1.6 mg per vial and is not interchangeable with bulk thymosin alpha-1 powder [1].

Can a US Pharmacy Compound It?

FDA's list for state-licensed pharmacies and physicians, updated May 14, 2026, does not include thymosin alpha-1 in any of its three categories [2]. On FDA's separate list for outsourcing facilities, updated March 21, 2025, it is in category 3, 'nominated without adequate support' [3]. FDA's category 1 policy, which generally means no action against compounders if conditions are met, does not apply to it [2][3].

FDA proposed not adding thymosin alpha-1 to the pharmacy bulks list. On December 4, 2024, the agency's Pharmacy Compounding Advisory Committee voted 4 yes and 17 no, with no abstentions, on adding both the free base and the acetate form; members who voted no cited no compelling evidence of clinical effectiveness and safety, and some who voted yes said patients should have access [4]. HHS's October 2026 draft enforcement-discretion policy covers six other peptides (BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500) and does not include thymosin alpha-1 [5]. No FDA or HHS action allowing compounding of this peptide has been found [5].

FDA's concerns are still posted. Thymosin alpha-1 appears in the 'nominated but withdrawn' table on FDA's page about bulk substances that may present significant safety risks; it had been in category 2 and came off that category when the nominators withdrew [6]. The stated concerns remain a 'significant risk for immunogenicity for certain routes of administration', peptide-impurity and characterization problems, and safety information 'inadequate for the agency to sufficiently understand the extent of any safety issues' [6].

Questions worth asking

Choose the questions you want to keep

What Does the Italian Zadaxin Label Say?

There is no US-approved dose [1]. The Italian Zadaxin label gives 1.6 mg subcutaneously or intramuscularly twice weekly for 4 weeks starting at the first vaccination, repeated from week 8 to week 12 at the second vaccination [1]. That label says the product is not for children, is contraindicated in pregnancy and breastfeeding, and calls for caution in people with allergies or autoimmune disease and with other immune-modulating drugs [1].

Check what you know

Think you have it? Try 3 quick questions and see what the article says.

1. How did the Pharmacy Compounding Advisory Committee vote on December 4, 2024, on adding thymosin alpha-1 to the pharmacy bulks list?

Question 1 of 3

Score: 0 right, 0 of 3 answered

Is thymosin alpha-1 legal in Virginia?
The federal information here does not establish whether or how it can be obtained legally in Virginia. Thymosin alpha-1 is not FDA-approved [1]. It is in none of FDA's three categories for state-licensed pharmacies and physicians [2], it is category 3, 'nominated without adequate support,' for outsourcing facilities [3], and FDA proposed not adding it to the pharmacy bulks list [4].
Why did the FDA advisory committee vote against it?
On December 4, 2024 the Pharmacy Compounding Advisory Committee voted 4 yes and 17 no, with no abstentions, on adding both the free base and the acetate form; members who voted no cited no compelling evidence of clinical effectiveness and safety, and some who voted yes said patients should have access [4].
Is thymosin alpha-1 on the WADA Prohibited List?
It is not named on WADA's 2026 Prohibited List [7]. WADA names thymosin-beta-4 and derivatives such as TB-500 in S2.3, which is a different peptide [7].
What dose does the Zadaxin label give?
In Italy the label gives 1.6 mg subcutaneously or intramuscularly twice weekly for 4 weeks from the first vaccination, repeated from week 8 to week 12 [1]. There is no US-approved dose [1].
Show all 7 referencesHide references
Evidence overview for Is Thymosin Alpha-1 Legal in Virginia? How to Access It Legally